[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glabellar-lines\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glabellar-lines":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100651040","a-study-to-evaluate-sequential-administration-of-injections-of-agn-151586-followed-by-botox-in-adult-participants-for-treatment-of-glabellar-lines-100651040",false,"NCT07756580","A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines","A Phase 1 Study to Evaluate the Safety and Efficacy of Sequential Administration of AGN-151586 and BOTOX® in Subjects for Treatment of Glabellar Lines (GL)","Inclusion Criteria:\n\n* Moderate or severe glabellar lines (GL) at maximum frown as assessed by both the investigator and participant using the Facial Wrinkle Scale (FWS) at Screening and Baseline (Day 1) Visits\n* Must be in good health as per investigator's judgment based on medical history, physical examination, vital sign measurements, and 12-lead ECG parameters\n* Must have sufficient visual acuity without the use of eyeglasses (contact lens use is acceptable) to accurately assess their GL, in the opinion of the investigator.\n\nExclusion Criteria:\n\n* Severe glabellar lines at rest as assessed by the investigator using the FWS\n* Prior exposure to botulinum neurotoxin of any serotype within the last 12 months prior to screening\n* History of hypersensitivity to any botulinum neurotoxin serotype or any other constituents of the study drug","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective sequential administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) is in adult participants with moderate to severe GL.\n\nAGN-151586 is an investigational drug being developed for treatment of moderate to severe glabellar lines. Participants are placed into 1 of 2 groups called treatment arms. In both arms participants will receive both AGN-151586 and BOTOX. Approximately 120 adult participants with moderate to severe glabellar lines enrolled in the study in approximately 8 sites around the United States.\n\nParticipants will receive injections of AGN-151586 on Day 1 in the glabellar complex. After meeting treatment criteria, participants in Cohort 1 will receive intramuscular injections of BOTOX on Day 14, and participants in Cohort 2 will receive intramuscular injections of BOTOX on Day 21. Participants will be followed for up to approximately 141 days.",[26],"Glabellar Lines",[26,28,29],"AGN-151586","BOTOX","NOT_YET_RECRUITING","2026-08-19",{"date":33,"type":34},"2026-08-20","ACTUAL",{"date":36,"type":20},"2026-08-10",{"date":38,"type":20},"2027-03",{"name":40,"class":41},"AbbVie","INDUSTRY",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100593964","phase-3-evaluate-the-efficacy-and-safety-of-dwp712-with-moderate-to-severe-glabellar-lines-100593964","NCT07013279","Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines","A Double-blind, Randomized, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy and Safety of DWP712 Inj. in Subjects With Moderate to Severe Glabellar Lines","Inclusion Criteria:\n\n\\- Subjects with a facial wrinkle scale (FWS) score of ≥2 (moderate) for glabellar lines at maximum frown in the investigator's on-site assessment at screening\n\nExclusion Criteria:\n\n\\- Subjects with glabellar lines that cannot sufficiently be improved by physical attempts, e.g., glabellar lines not flattened by hand, in the judgment of the investigator",true,"19 Years","65 Years",{"count":53,"type":20},324,[55],"PHASE3","To evaluate the efficacy and safety of DWP712 Inj. in Subjects with Moderate to Severe Glabellar Lines",[26],"2025-06-02",{"date":60,"type":34},"2025-06-10",{"date":62,"type":20},"2025-07-15",{"date":64,"type":20},"2026-03-31",{"name":66,"class":41},"Daewoong Pharmaceutical Co. LTD.",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":49,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":67},"100531899","phase-3-to-evaluate-hu-045-in-the-treatment-of-glabellar-linesphase-iii-100531899","NCT06205797","To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)","A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HU-045 Compared to Xeomin® in Adult Patients With Moderate or Severe Glabellar Lines","Inclusion Criteria:\n\n* 19 Years to 65 Years(Adult, Older Adult)\n* 2(Moderate) and\u002For above of Facial Wrinkle Scale (FWS) score at frown in investigator's live assessment.\n* Subject who signed voluntarily in informed consent form and fully understood about this clinical trial.\n\nExclusion Criteria:\n\n* Subject who has history of any diseases following. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)\n* History of bleeding disorder\n* Infection, dermatological condition or scar at the treatment injection sites\n* Subject who has marked facial asymmetry\n* History of facial nerve palsy or eyebrow\u002Feyelid ptosis\n* History of surgical procedures affecting on the lines of forehead and\u002For middle of the forehead areas\n* History of malignant tumor within 5 years (except for basal cell carcinoma\n* Any disease and condition that, in the view of the investigator, would interfere with study participation\n* History of alcohol or drug addiction\n* Subject who has been treated with any botulinum toxin drug within 6 months\n* Persons who have received the following drugs with systemic muscle relaxant action within 4 weeks of screening\n* Subjects taking more than 1,000 IU\u002Fday of anticoagulants, antiplatelet agents, NSAIDs, or vitamin E within 7 days prior to administration of the investigational drug (excluding low-dose aspirin)\n* A person who has received a retinoid series of medications during the following period as of the time of screening\n* Subjects who have hypersensitivity reaction to investigational drug or local anesthetics\n* History of Anaphylaxis or severe combined allergy disease\n* Subject who has physically untreatable glabellar lines like that can't be spread out even if someone forces it to spread out\n* Pregnant and lactating women F- ertile women and men who have plans to pregnancy and who do not agree to appropriate contraception.\n* Participant who has been treated with any investigational drug within 30 days from screening\n* Subject who are not eligible for this study based on investigator's judgement.",{"count":76,"type":20},312,[55],"A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines",[26],"RECRUITING","2024-10-01",{"date":83,"type":34},"2024-10-03",{"date":85,"type":34},"2024-06-20",{"date":87,"type":20},"2025-03-31",{"name":89,"class":41},"Huons Biopharma"]